Surface Antigens (Surface Antigen)

Subscribe to Selected New Research on Surface Antigens

3817 relevant articles (84 outcomes, 284 trials/studies) found for this Bio-Agent

Description: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.

Also Known As:

Surface Antigen; Surface Antigens, Cell; Antigens, Surface; Cell Surface Antigen; Immunologic Surface Markers; Markers, Immunological Surface; Surface Markers, Immunologic; Antigen, Cell Surface; Antigen, Surface; Antigens, Cell Surface; Immunological Surface Markers; Markers, Immunologic Surface; Surface Antigen, Cell; Cell Surface Antigens; Surface Markers, Immunological

Relationship Network

Bio-Agent Context: Research Results

Biological Factors: 931

Antigens: 95584

Surface Antigens: 3817

Blood Group Antigens: 1507

Cell Adhesion Molecules: 1503

Histocompatibility Antigens: 1201

Differentiation Antigens: 874

Leukocyte L1 Antigen Complex: 325

human glutamate carboxypeptidase II: 307

Arrestin: 201

OspA protein: 138

K antigens: 96

L-selectin counter-receptors: 21

rat endothelial barrier antigen: 14

Minor Lymphocyte Stimulatory Antigens: 9

K99 antigen: 8

ELAV-like protein 1: 5

mouse Q5 antigen: 4

rat Ran 2 protein: 2

bovine betaE11 antigen: 1

horse ELY-1 antigen: 1

human 6C6 antigen: 1

human NZ-2 testis-specific antigen: 1

human oval cell antigen: 1

liver cell membrane specific antigen: 1

Lymphocyte Antigen 96: 1

mouse NORM-2 antigen: 1

sheep Lp antigen: 1

Trypanosoma Variant Surface Glycoproteins: 1

avian Marek's disease tumor-associated surface antigen

Borrelia hermsii Vmp24 protein

Borrelia hermsii Vmp3 protein

Burkholderia pseudomallei surface antigen 8

chol-1 antigen

Echinococcus multilocularis Elp protein

Ehrlichia P50 protein

endothelial cell-monocyte antigens

Entamoeba histolytica 29 kDa antigen

Gallus thrombomucin protein

Giardia cysteine-rich protein 170

Giardia cysteine-rich protein 72

Giardia lamblia TSA 417 protein

group B streptococci alpha C protein

H63 antigen

honeybee antigen A2B7

human blood dendritic cell antigen 3

human blood dendritic cell antigen 4

human CD200R1 protein

human CD300C protein

human CTAG2 protein

human disialosyl-T antigen

human EGP-2 antigen

human EMILIN3 protein

human ETAA1 protein

human EXOSC5 protein

human GP 40-80 glycoprotein

human SPAG11A protein

human SPAG11B protein

human SPAG8 protein

human sperm antigen 80-kDa

human SSFA2 protein

human STRO-1 antigen

human testis-specific contraceptive vaccinogen

human TM-316 antigen

human TM4SF1 protein

human TRA-1-60 antigen

human TRA-1-81 antigen

kell-active proteins

Lawsonia intracellularis LsaA protein

Leishmania major S3a-related protein

Leishmania surface antigen P2

Leishmania surface antigen protein

lymphokine-activated cell-associated antigen

MLR3 activation antigen

mouse 5T4 protein

mouse antigen 3G11

mouse Cd200r1 protein

mouse Cd207 protein

mouse extra sheep E antigen

mouse GP 90 nephritis antigen

mouse Ly64 protein

mouse Ly86 protein

mouse M(M)120-1 antigen

mouse Maged2 protein

Experts

1.	Hviid, Lars: 10 articles (06/2008 - 04/2002)
2.	Staalsoe, Trine: 9 articles (06/2008 - 04/2002)
3.	Theander, Thor G: 6 articles (06/2008 - 04/2002)
4.	Marsh, Kevin: 5 articles (11/2005 - 02/2002)
5.	Akanmori, Bartholomew D: 4 articles (06/2008 - 04/2002)
6.	Bull, Peter C: 4 articles (11/2005 - 02/2002)
7.	Dodoo, Daniel: 3 articles (06/2008 - 04/2002)
8.	Nielsen, Morten A: 3 articles (06/2008 - 04/2002)
9.	Ofori, Michael F: 3 articles (05/2006 - 06/2002)
10.	Theander, T G: 3 articles (03/2006 - 02/2000)

Related Diseases

1.	Infection 12/01/1975 - "The results indicate that the surface-antigen-adsorbed vaccine induced high titres of serum antibody, and gave significant protection against challenge infection." 04/01/2006 - "Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice." 03/30/1991 - "Two regimens by which vaccine was injected intradermally into children between 0 and 4 years old led to peak geometric mean (95% CI) concentrations of antibody against HBV surface antigen of 270 (202-358) and 555 (418-748) mlU/ml. The third regimen--intramuscular vaccination of children aged between 0 and 4 years--gave geometric mean peak antibody concentrations of 926 (765-1122) mlU/ml. A fourth regimen was intramuscular vaccination of children between 1 and 9 months old, which gave geometric mean antibody concentrations of 5431 (3903-75,456) mlU/ml. Despite these widely divergent responses and a 89% decay in antibody over the first 2 years, vaccination against HBV was 97% effective in preventing chronic infection. " 03/01/1976 - "The vaccine is based on the premise that antibody to the surface antigen of the hepatitis B virus is protective against viral infection. " 08/01/2008 - "Maybe the HBV strains in this study represent a natural end-stage of seemingly cleared HBV infection, in which HBV maintains a low level of possibly non-infectious replication, after sacrificing its immunologically offending surface antigen, thus avoiding final clearance by the immune system." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 03/01/2005 - "Challenges that remain to be addressed if the full potential of primary cultures as a model system is to be realized include isolation, culture and characterization of stem cells, improved methodology to induce or maintain a fully differentiated, androgen-responsive phenotype, and identification of cell surface antigens or other markers with which to purify pure populations of live cancer or premalignant cells apart from non-malignant epithelial cells prior to culture." 10/20/2003 - "Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density-dependent manner." 06/01/2003 - "Radiolabelled MAbs against cell surface antigens have improved in vivo tumor diagnosis and treatment. " 08/15/2001 - "Using a series of human tumor cells (SNB19, SNB79, 143N2, and SHEP), we observed a distinct efficacy of human anti-FasR antibody with an apparent correlation with Fas cell surface antigen expression. " 01/01/1992 - "Uptake in tumor could be improved by using either a radiolabel that is retained intracellularly, 111In-DTPA (18.5% ID/g at 24 h), or by targeting a surface antigen that does not internalize upon antibody binding, CD45 (20.5% ID/g at 24 h). " Order ALL the reference details at left...
3.	Hepatitis B 08/01/2006 - "The study describes expression and purification of recombinant hepatitis B small surface antigen (rHBsAg hereafter) in methylotrophic yeast Pichia pastoris strain GS115. " 10/01/1990 - "The results of these studies were correlated with the histopathology and immunohistochemical stains for hepatitis B core and surface antigens. " 08/01/2009 - "High level virion production and surface antigen expression with 1.5 copies of hepatitis B viral genome." 07/01/2006 - "On the 14th hospital day, surface antigen seroconversion was noted with undetectable hepatitis B virus surface antigen (HBs Ag) and low titre of anti-HBs antibody, indicating a complete recovery from acute fulminant hepatitis B. " 05/15/2006 - "Recombinant hepatitis B large surface antigen, successfully produced in Escherichia coli, stimulates T-cell response in mice." Order ALL the reference details at left...
4.	Lymphoma (Lymphomas) 08/29/1986 - "To investigate the mechanism of glycophospholipid anchoring of the surface antigen Thy-1, we have undertaken a comparative biosynthetic study using a wild-type Thy-1+ murine T lymphoma (BW5147) and a mutant T lymphoma (class E) that synthesizes Thy-1 but fails to express it on the plasma membrane. " 05/15/1972 - "Quantitative studies on the binding of syngeneic antibody to the surface antigens of AKR-virus-induced rat lymphoma cells." 02/01/2008 - "Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56). " 12/07/2006 - "Here, we analyse apoptosis events in the thymic lymphoma cell line Thy278, which expresses cell surface antigens characteristic of immature double positive thymocytes. " 07/01/2006 - "The array carried 667 BAC clones densely selected for the genomic regions not only of lymphoma-related loci but also of surface antigen receptors, enabling immunogenotyping. " Order ALL the reference details at left...
5.	Hepatitis 05/01/2003 - "For hepatitis surface antigen expression in eukaryotic cells, the vector pRc/CMV is superior to pSG5UTPL/Flag, and pRc/CMV-S and pRc/CMV-MS are the most efficient in the pRc/CMV clones. " 03/12/2007 - "METHODS: Analysis comprised HIV-positive patients in the ICoNA study without acute hepatitis who had >or= 1 positive HCV antibody test and > 1 positive HBV surface antigen test. " 09/01/1996 - "During the study period of 28 days, protective antibody titers to hepatitis surface antigen (anti-HBs10 mIU ml-1) were observed in 11 of 81 subjects receiving rhGM-CSF, but in none of the controls (P = 0.035). " 04/01/2008 - "Viral hepatitis, then the principal risk of transfusion, engaged me in the molecular analyses of purified hepatitis B virus (HBV) and its surface antigen. " 01/01/2008 - "Seventy-six percent of the vaccinated patients (HBV vaccine) developed anti-HBs (antibody to hepatitis surface antigen) >or=10 UI/L. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antigens
2.	Hepatitis B Surface Antigens (HBsAg)
3.	Antibodies
4.	DNA (Deoxyribonucleic Acid)
5.	Hepatitis B e Antigens
6.	Monoclonal Antibodies
7.	Immunoglobulin G (IgG)
8.	Surface Antigens (Surface Antigen)
9.	rituximab (Mabthera)
10.	Interferon-alpha (Interferon Alfa)

Related Therapies and Procedures

1.	Immunotherapy
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Highly Active Antiretroviral Therapy (HAART)
5.	Radioimmunotherapy

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>